All In Biotech

Drug Trial Radar · NCT07502638

FXS6837 for the Treatment of IgAN Patients

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of FXS6837 in IgAN Patients

Last checked: Nov 19, 2026Latest source record: Mar 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Mar 31, 2026

Primary completion

Sep 12, 2027

Study completion Nov 14, 2027

Sponsor

Sponsor type
Industry
First posted
Mar 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo controlled Phase IIb study to explore the efficacy and safety of FXS6837 capsules in IgAN patients. About 60 patients dignosed with primary IgAN will be enrolled and randomized to three cohorts and take different dosage of FXS6837 or placebo capsules orally according to protocol.

Conditions

  • IgAN

Interventions

  • FXS6837 Dose 1Drug

    FXS6837 taken orally once a day

  • FXS6837 Dose 2Drug

    FXS6837 taken orally once a day

  • Placebo CapsuleDrug

    Placebo taken orally once a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ratio to baseline in Urine Protein to Creatinine Ratio (sampled from 24h urine collection) at Day180Time frame: baseline and Day180

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.